Fig. 2From: Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patientsKaplan–Meier curves for progression-free survival probabilities stratified by Fulvestrant lines (a), lymph node metastasis (b), visceral metastasis (c), and prior palliative chemotherapy (d). The left panel was derived from enrolled raw dataset; the right panel showed KM curves for propensity score-matched samplesBack to article page